SCHEMBL18955869

SCHEMBL18955869

Cc1cnc(-c2ccccc2O)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.45
CASP3 P42574 3/20 0.44
SENP8 Q96LD8 3/20 0.44
SENP7 Q9BQF6 3/20 0.44
SENP6 Q9GZR1 3/20 0.44
RAB9A P51151 6/20 0.43
NPC1 O15118 5/20 0.43
HPGD P15428 5/20 0.42
HSD17B10 Q99714 4/20 0.42
KDM4E B2RXH2 4/20 0.42
TSHR P16473 2/20 0.42
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
CHUK O15111 2/20 0.41
TXNRD1 Q16881 2/20 0.41
NOX4 Q9NPH5 2/20 0.41
KMT2A Q03164 3/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 5/20 0.40
CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23176766 0.81 RAB9A (0.59) CASP3SENP8SENP7SENP6RAB9A
SCHEMBL30288200 0.79 NPC1 (0.49) TTRCASP3SENP8SENP7SENP6
Methyl Alcohol SCHEMBL27795304 0.79 NPC1 (0.45) RAB9ANPC1HPGDHSD17B10KDM4E
SCHEMBL12794312 0.79 EDNRB (0.39) CASP3SENP8SENP7SENP6RAB9A
SCHEMBL13086663 0.78 NPC1 (0.60) CASP3SENP8SENP7SENP6RAB9A
SCHEMBL1207825 0.78 NPC1 (0.45) CASP3SENP8SENP7SENP6RAB9A
SCHEMBL5540045 0.78 KDM4E (0.59) RAB9ANPC1HPGDHSD17B10KDM4E
SCHEMBL2288771 0.78 C1R (0.43) CASP3SENP8SENP7SENP6RAB9A
SCHEMBL19484241 0.77 RAB9A (0.65) RAB9ANPC1KDM4ETSHRKMT2A
SCHEMBL10186915 0.77 PDCD1 (0.42) CASP3SENP8SENP7SENP6RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119968377-A Phosphoramidate compounds and uses thereof 安锐生物医药公司 2025-05-09 CN disclosed
US-11638706-B2 Methods for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-05-02 US disclosed
US-11608501-B2 Methods for modifying RNA splicing PTC THERAPEUTICS, INC. (US) 2023-03-21 US disclosed
EP-3638318-A1 METHODS FOR MODIFYING RNA SPLICING PTC Therapeutics, Inc. (US) 2020-04-22 EP disclosed
WO-2018232039-A1 METHODS FOR MODIFYING RNA SPLICING PTC THERAPEUTICS, INC. (US) 2018-12-20 WO disclosed
EP-3386511-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2018-10-17 EP disclosed
WO-2017100726-A1 METHODS FOR TREATNG HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2017-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11608501-B2 Methods for modifying RNA splicing RBM17, SNRPA1, SNRPE TTR 3302/4885CASP3 4188/4885SENP8 2039/4885
US-11638706-B2 Methods for treating Huntington's disease HTT, HYPK, FH TTR 27/4885CASP3 1949/4885SENP8 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.